All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results ConPlas-19, 2020 0.56 [0.20; 1.57]
DAWN-Plasma, 2021 0.61 [0.24; 1.55]
NCT04397757, 2021 0.47 [0.04; 5.45]
Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
VERU-111, 2022 0.30 [0.14; 0.64]
0.62 [0.31 ; 1.24 ] ConPlas-19, 2020, DAWN-Plasma, 2021, NCT04397757, 2021, Sekine (PLACOVID), 2021, VERU-111, 2022 5 51% 1,222 moderate not evaluable death D28detailed results Abdulamir, 2021 1.00 [0.20; 5.12]
Abuhasira, 2021 0.72 [0.23; 2.24]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
Amra, 2021 0.47 [0.12; 1.93]
ASCOT, 2021 0.60 [0.06; 5.99]
Bennett-Guerrero, 2021 0.86 [0.24; 3.11]
Cadegiani, 2021 0.22 [0.16; 0.31]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.12 [0.86; 1.46]
ConPlas-19, 2020 0.49 [0.20; 1.19]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
Davoudi-Monfared, 2020 0.30 [0.11; 0.83]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
FACCT Trial, 2021 0.69 [0.28; 1.68]
Fragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.62 [0.33; 1.17]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
Gharebaghi, 2020 0.00 [0.00; 0.09]
GLUCOCOVID, 2020 0.63 [0.25; 1.60]
GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
Guardado-Mendoza, 2022 0.32 [0.06; 1.72]
Gunst JD, 2021 0.99 [0.29; 3.42]
Horby, 2021 1.01 [0.93; 1.10]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
ITAC, 2022 0.80 [0.42; 1.52]
Jamaati, 2021 1.19 [0.38; 3.72]
Jun C, 2020 1.00 [0.02; 53.89]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kirenga, 2021 1.25 [0.46; 3.39]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Lanzoni, 2021 0.14 [0.02; 0.96]
Li, 2020 0.59 [0.22; 1.59]
LIFESAVER, 2021 2.00 [0.16; 24.66]
Mahajan, 2021 1.23 [0.34; 4.42]
Menichetti, 2021 0.75 [0.37; 1.53]
Metcovid, 2020 0.92 [0.67; 1.28]
Mobarak (DISCOVER), 2021 1.15 [0.83; 1.59]
Mobarak S (DISCOVER), 2021 1.10 [0.77; 1.57]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PICP19 (Ray), 2020 0.67 [0.30; 1.51]
PLACID, 2020 1.04 [0.66; 1.63]
PLACO-COVID, 2021 1.71 [0.72; 4.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2020 1.09 [0.97; 1.23]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
REMAP-CAP, fixed 7-day course, 2020 1.03 [0.54; 1.98]
REMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.59 [0.33; 1.06]
Sakoulas, 2020 0.29 [0.03; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shahbaznejad, 2020 2.21 [0.07; 67.87]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Silva, 2021 0.46 [0.03; 8.02]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Tang X, 2020 0.98 [0.93; 1.02]
TOCOVID, 0 0.99 [0.02; 50.02]
University of Minnesota, 2020 1.29 [0.51; 3.26]
Veiga, 2021 2.70 [0.92; 7.92]
Zhang, 2020 0.50 [0.17; 1.50]
0.85 [0.80 ; 0.91 ] Abdulamir, 2021, Abuhasira, 2021, ACTT-2 (Kalil), 2020, AlQahtani, 2020, Aman, 2021, Amra, 2021, ASCOT, 2021, Bennett-Guerrero, 2021, Cadegiani, 2021, CAN-COVID, 2020, Co-CLARITY, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Davoudi-Monfared, 2020, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, FACCT Trial, 2021, Fragoso-Saavedra (PISCO), 2020, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Gharebaghi, 2020, GLUCOCOVID, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Guardado-Mendoza, 2022, Gunst JD, 2021, Horby, 2021, HYDRA (Hernandez-Cardenas), 2021, I-TECH (Lim), 2022, ITAC, 2022, Jamaati, 2021, Jun C, 2020, Kalil (ACTT-3), 2021, Kirenga, 2021, Krolewiecki, 2020, Lanzoni, 2021, Li, 2020, LIFESAVER, 2021, Mahajan, 2021, Menichetti, 2021, Metcovid, 2020, Mobarak (DISCOVER), 2021, Mobarak S (DISCOVER), 2021, NCT04377750 (HMO-0224-20), 0, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, NIH NIAID ACTT-1, 2020, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PICP19 (Ray), 2020, PLACID, 2020, PLACO-COVID, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, RAPID (Sholzberg), 2021, RECOVER, 2021, RECOVERY, 2020, RECOVERY, 2022, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shahbaznejad, 2020, Shashi Bhushan, 2021, Shi, 2020, Shu, 2020, Silva, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, SOLIDARITY (WHO study) HCQ, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Tabarsi, 2020, Talaschian, 2021, Tang X, 2020, TOCOVID, 0, University of Minnesota, 2020, Veiga, 2021, Zhang, 2020 107 52% 101,670 moderate critical death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
COLCHIVID, 2021 0.83 [0.35; 1.95]
Duarte, 2020 0.57 [0.18; 1.79]
GLUCOCOVID, 2020 0.68 [0.37; 1.25]
Gunst JD, 2021 0.55 [0.26; 1.17]
Lopardo, 2021 0.65 [0.35; 1.22]
PLACID, 2020 1.07 [0.73; 1.57]
RAPID (Sholzberg), 2021 0.70 [0.44; 1.12]
RECOVERY, 2020 1.09 [0.99; 1.20]
0.88 [0.73 ; 1.07 ] BACC Bay Tocilizumab Trial, 2020, COLCHIVID, 2021, Duarte, 2020, GLUCOCOVID, 2020, Gunst JD, 2021, Lopardo, 2021, PLACID, 2020, RAPID (Sholzberg), 2021, RECOVERY, 2020 9 32% 6,594 moderate serious deathsdetailed results Abd-Elsalam, 2020 1.21 [0.36; 4.12]
Abd-Elsalam, 2021 0.74 [0.16; 3.42]
Abdulamir, 2021 1.00 [0.20; 5.12]
ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
Ansarin, 2020 0.09 [0.00; 1.68]
ARCHAIC -hydroxychloroquine, 2020 5.00 [0.13; 185.58]
ASCOT, 2021 0.60 [0.06; 5.99]
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.88 [0.64; 1.20]
BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
Cadegiani, 2021 0.16 [0.11; 0.24]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Cao, 2020 0.71 [0.36; 1.40]
CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
CAPSID, 2021 0.84 [0.28; 2.50]
CCAP-1, 2020 1.00 [0.00; 255.63]
CCAP-2, 2021 2.03 [0.61; 6.77]
Chen, 2020 0.56 [0.01; 30.20]
Chen, ChiCTR2000030054 - Chloroquine, 2020 0.66 [0.01; 35.52]
ChiCTR2000030054-HCQ (Chen), 2020 0.66 [0.01; 35.52]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
COALIZAO ACTION, 2021 1.55 [0.90; 2.70]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCHIVID, 2021 0.69 [0.20; 2.40]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59]
CONFIDENT, 2020 0.84 [0.52; 1.37]
ConPlas-19, 2020 0.46 [0.19; 1.15]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COP-COVID-19, 2021 0.96 [0.36; 2.56]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
COVID MED (losartan), 2021 3.20 [0.25; 41.21]
COVID-VIT-D, 2022 1.48 [0.75; 2.92]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
CPC-SARS, 2021 0.04 [0.01; 0.26]
Dabbous HM, 2020 0.51 [0.02; 15.41]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
DEVENT, 0 0.47 [0.22; 1.00]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Duarte, 2020 0.45 [0.08; 2.60]
Duke university HCQ, 2020 1.00 [0.02; 50.40]
Duke university HCQ-AZI, 2020 3.00 [0.04; 207.00]
Duke University hydroxychloroquine/azithromycine, 2020 0.50 [0.01; 19.56]
Edalatifard, 2020 0.29 [0.15; 0.56]
EMPACTA, 2020 1.13 [0.54; 2.40]
Entrenas (Pilot Calcifediol), 2020 0.12 [0.01; 2.79]
Esquivel-Moynelo, 2020 1.10 [0.02; 57.31]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
FACCT Trial, 2021 0.96 [0.44; 2.08]
Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
Fu, 2020 1.00 [0.02; 51.66]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.62 [0.33; 1.17]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
Gharebaghi, 2020 0.00 [0.00; 0.09]
GLUCOCOVID, 2020 0.63 [0.25; 1.60]
Gonzalez (HCQ), 2020 0.33 [0.06; 1.78]
Gonzalez (IVER), 2020 0.83 [0.23; 3.02]
GRECCO-19, 2020 0.21 [0.02; 1.97]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
Gunst JD, 2021 0.70 [0.20; 2.49]
Hamed, 2021 1.83 [0.16; 21.66]
Hashim A, 2020 0.48 [0.11; 1.99]
HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89]
Holm K, 2021 0.49 [0.08; 2.89]
Horby, 2021 1.01 [0.93; 1.10]
HYCOVID, 2020 0.54 [0.21; 1.40]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
ILBS-COVID-02 (Bajpai M), 2020 3.82 [0.35; 41.96]
INSPIRATION, 2021 1.09 [0.78; 1.53]
ITAC, 2022 0.80 [0.42; 1.52]
Jamaati, 2021 1.19 [0.38; 3.72]
Jamali Moghadam Siahkali, 2021 1.00 [0.19; 5.40]
Jun C, 2020 1.00 [0.02; 53.89]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Khamis, 2020 0.83 [0.23; 2.96]
Kirenga, 2021 1.25 [0.46; 3.39]
Kirti, 2021 0.12 [0.01; 2.36]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Kumar, 2021 0.06 [0.00; 1.35]
Kumari, 2020 0.60 [0.22; 1.64]
LACCPT, 2021 1.17 [0.58; 2.36]
Lanzoni, 2021 0.11 [0.01; 0.93]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Li, 2020 0.59 [0.22; 1.59]
Libster, 2020 0.50 [0.09; 2.71]
LIFESAVER, 2021 2.00 [0.16; 24.66]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Lopardo, 2021 0.57 [0.24; 1.37]
Lopes MIF, 2020 1.06 [0.02; 56.61]
Lou (FAVIPIRAVIR), 2020 1.12 [0.02; 62.74]
Lou Y, 2020 1.00 [0.02; 55.80]
Mahajan, 2021 1.23 [0.34; 4.42]
Menichetti, 2021 0.75 [0.37; 1.53]
Metcovid, 2020 0.92 [0.67; 1.28]
Ming Zhong, 2020 0.17 [0.02; 1.44]
Mobarak (DISCOVER), 2021 1.15 [0.83; 1.59]
Mobarak S (DISCOVER), 2021 1.15 [0.80; 1.67]
Murai, 2020 1.53 [0.53; 4.43]
Murugesan, 2022 1.00 [0.02; 51.41]
NCT04333654, 2020 0.56 [0.01; 37.57]
NCT04342650, 2020 0.95 [0.02; 48.42]
NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55]
NCT04385199, 2021 0.75 [0.15; 3.77]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04442191, 2021 0.11 [0.00; 143.68]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04542694, 2020 1.00 [0.02; 50.90]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
OAHU-COVID19, 2020 2.75 [0.10; 73.35]
Okumuş, 2020 0.58 [0.18; 1.91]
ORCHID, 2020 1.07 [0.54; 2.11]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
Patel, 2021 0.77 [0.11; 5.34]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PICP19 (Ray), 2020 0.67 [0.30; 1.51]
PLACID, 2020 1.04 [0.66; 1.63]
PLACO-COVID, 2021 1.71 [0.72; 4.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
ProPAC-COVID, 2021 0.08 [0.00; 8.65]
PROTECT A, 2020 0.50 [0.02; 15.30]
PROTECT B, 2020 0.51 [0.04; 6.12]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
Rasheed, 2020 0.13 [0.01; 1.09]
RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2020 1.09 [0.97; 1.23]
RECOVERY, 2020 1.03 [0.91; 1.17]
RECOVERY, 2021 0.85 [0.76; 0.95]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
REMAP-CAP sarilumab, 2021 0.51 [0.25; 1.07]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.08 [0.85; 1.38]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
REMAP-CAP-HCQ, 2020 1.04 [0.49; 2.19]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
Rocco, 2020 1.02 [0.02; 51.70]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
Sadeghi , 2020 0.56 [0.12; 2.56]
Sakoulas, 2020 0.29 [0.03; 3.13]
Salehzadeh, 2020 1.00 [0.02; 51.41]
sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80]
sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Sekhavati, 2020 0.49 [0.02; 14.80]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shenoy S, 2021 1.32 [0.58; 2.99]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55]
SOLIDARITY (interferon), 2020 1.16 [0.96; 1.40]
SOLIDARITY (lopi/rito), 2020 1.00 [0.79; 1.26]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
SPRINTER, 2022 0.79 [0.38; 1.66]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
Tang, 2020 1.00 [0.02; 51.07]
Tang X, 2020 0.98 [0.93; 1.02]
TEACH, 2020 1.07 [0.34; 3.37]
TOCOVID, 0 0.99 [0.02; 50.02]
Udwadia, 2020 0.50 [0.02; 15.03]
University of Minnesota, 2020 0.68 [0.11; 4.16]
Veiga, 2021 2.70 [0.92; 7.92]
Yakoot, 2020 0.38 [0.07; 2.08]
Zhang, 2020 0.50 [0.17; 1.50]
Zhaowei Chen, 2020 1.00 [0.02; 52.04]
0.87 [0.83 ; 0.91 ] Abd-Elsalam, 2020, Abd-Elsalam, 2021, Abdulamir, 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, AlQahtani, 2020, Aman, 2021, Ansarin, 2020, ARCHAIC -hydroxychloroquine, 2020, ASCOT, 2021, ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, BACC Bay Tocilizumab Trial, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, Cadegiani, 2021, CAN-COVID, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, CAPE-COVID, 2020, CAPSID, 2021, CCAP-1, 2020, CCAP-2, 2021, Chen, 2020, Chen, ChiCTR2000030054 - Chloroquine, 2020, ChiCTR2000030054-HCQ (Chen), 2020, Co-CLARITY, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COALIZAO ACTION, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, COLCHIVID, 2021, COLCOVID, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COP-COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, COVID MED (losartan), 2021, COVID-VIT-D, 2022, CP-COVID-19, 2021, CPC-SARS, 2021, Dabbous HM, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, DEVENT, 0, DEXA-COVID19, 2020, Duarte, 2020, Duke university HCQ, 2020, Duke university HCQ-AZI, 2020, Duke University hydroxychloroquine/azithromycine, 2020, Edalatifard, 2020, EMPACTA, 2020, Entrenas (Pilot Calcifediol), 2020, Esquivel-Moynelo, 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, FACCT Trial, 2021, Fragoso-Saavedra (PISCO), 2020, Fu, 2020, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Gharebaghi, 2020, GLUCOCOVID, 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, GRECCO-19, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Hamed, 2021, Hashim A, 2020, HC-nCoV (Shanghai), 2020, Holm K, 2021, Horby, 2021, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, I-TECH (Lim), 2022, ILBS-COVID-02 (Bajpai M), 2020, INSPIRATION, 2021, ITAC, 2022, Jamaati, 2021, Jamali Moghadam Siahkali, 2021, Jun C, 2020, Kalil (ACTT-3), 2021, Khamis, 2020, Kirenga, 2021, Kirti, 2021, Krolewiecki, 2020, Kumar, 2021, Kumari, 2020, LACCPT, 2021, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Libster, 2020, LIFESAVER, 2021, LIVE-AIR (Temesgen), 2021, Lopardo, 2021, Lopes MIF, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Mahajan, 2021, Menichetti, 2021, Metcovid, 2020, Ming Zhong, 2020, Mobarak (DISCOVER), 2021, Mobarak S (DISCOVER), 2021, Murai, 2020, Murugesan, 2022, NCT04333654, 2020, NCT04342650, 2020, NCT04377750 (HMO-0224-20), 0, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04442191, 2021, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04523831 (Mahmud), 2020, NCT04528368, 2021, NCT04542694, 2020, NCT04577534 (COVIDSTORM), 0, NIH NIAID ACTT-1, 2020, NO COVID-19 (Lyngbakken), 2020, NOR-Solidarity (hydroxychloroquine), 2021, OAHU-COVID19, 2020, Okumuş, 2020, ORCHID, 2020, O’Donnell, 2021, Pandit, 2021, Patel, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PICP19 (Ray), 2020, PLACID, 2020, PLACO-COVID, 2021, PlasmAr, 2020, Pouladzadeh, 2021, ProPAC-COVID, 2021, PROTECT A, 2020, PROTECT B, 2020, Rahmani, 2020, Raman, 2021, RAPID (Sholzberg), 2021, Rasheed, 2020, RCT-TCZ-COVID-19, 2021, RECOVER, 2021, RECOVERY, 2020, RECOVERY, 2020, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, REMAP-CAP-HCQ, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, Sadeghi , 2020, Sakoulas, 2020, Salehzadeh, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SAVE-MORE, 2021, Sekhavati, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shenoy S, 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, SOLIDARITY (interferon), 2020, SOLIDARITY (lopi/rito), 2020, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, SPRINTER, 2022, Steroids-SARI, 2020, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tabarsi, 2020, Talaschian, 2021, Tang, 2020, Tang X, 2020, TEACH, 2020, TOCOVID, 0, Udwadia, 2020, University of Minnesota, 2020, Veiga, 2021, Yakoot, 2020, Zhang, 2020, Zhaowei Chen, 2020 225 37% 154,448 moderate critical deaths (time to event analysis only)detailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
Cadegiani, 2021 0.16 [0.11; 0.24]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConPlas-19, 2020 0.46 [0.19; 1.15]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Edalatifard, 2020 0.29 [0.15; 0.56]
Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
Gunst JD, 2021 0.70 [0.20; 2.49]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lanzoni, 2021 0.11 [0.01; 0.93]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
PlasmAr, 2020 0.93 [0.47; 1.85]
RECOVERY, 2020 1.09 [0.97; 1.23]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45]
REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Talaschian, 2021 1.25 [0.30; 5.14]
Zhang, 2020 0.50 [0.17; 1.50]
0.78 [0.69 ; 0.88 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTT-2 (Kalil), 2020, Baldeon, 2022, Bennett-Guerrero, 2021, Cadegiani, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, COV-BARRIER, 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Davoudi-Monfared, 2020, DAWN-Plasma, 2021, Edalatifard, 2020, Fragoso-Saavedra (PISCO), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lanzoni, 2021, LIVE-AIR (Temesgen), 2021, NIH NIAID ACTT-1, 2020, NOR-Solidarity (hydroxychloroquine), 2021, PlasmAr, 2020, RECOVERY, 2020, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Talaschian, 2021, Zhang, 2020 41 74% 51,420 moderate critical clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64]
CAPSID, 2021 0.63 [0.29; 1.40]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
COALIZAO ACTION, 2021 1.35 [0.85; 2.15]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58]
ConPlas-19, 2020 1.00 [0.65; 1.53]
CONTAIN COVID-19, 2021 0.94 [0.75; 1.18]
CORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92]
CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
COV-BARRIER, 2021 1.12 [0.58; 2.16]
ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57]
ELACOI (Standard of care), 2020 0.86 [0.06; 11.36]
EMPACTA, 2020 0.55 [0.33; 0.92]
Esquivel-Moynelo, 2020 2.29 [0.20; 26.58]
GRECCO-19, 2020 0.11 [0.01; 1.08]
Hashim A, 2020 0.40 [0.10; 1.63]
I-TECH (Lim), 2022 1.25 [0.87; 1.80]
Jun C, 2020 2.07 [0.06; 66.79]
Kamran, 2020 0.95 [0.32; 2.78]
Kirenga, 2021 0.91 [0.38; 2.17]
Li T, 2020 0.48 [0.01; 27.44]
Libster, 2020 0.52 [0.29; 0.94]
NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
PLACID, 2020 1.04 [0.54; 1.99]
RAPID (Sholzberg), 2021 0.69 [0.43; 1.10]
RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.53 [0.15; 1.95]
Rocco, 2020 1.02 [0.29; 3.58]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
Shu, 2020 0.27 [0.01; 5.58]
Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77]
SPRINTER, 2022 0.69 [0.43; 1.11]
STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
Tang X, 2020 1.00 [0.13; 7.45]
TEACH, 2020 1.80 [0.62; 5.21]
Zhang, 2020 0.40 [0.10; 1.65]
Zhaowei Chen, 2020 0.11 [0.01; 2.19]
0.79 [0.68 ; 0.91 ] BACC Bay Tocilizumab Trial, 2020, CAP-China (Wang et al.), 2020, CAPSID, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALIZAO ACTION, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, COV-BARRIER, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, EMPACTA, 2020, Esquivel-Moynelo, 2020, GRECCO-19, 2020, Hashim A, 2020, I-TECH (Lim), 2022, Jun C, 2020, Kamran, 2020, Kirenga, 2021, Li T, 2020, Libster, 2020, NCT04523831 (Mahmud), 2020, PLACID, 2020, RAPID (Sholzberg), 2021, RCT-TCZ-COVID-19, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, SAVE-MORE, 2021, Shu, 2020, Soin AS (COVINTOC), 2021, SPRINTER, 2022, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020, TEACH, 2020, Zhang, 2020, Zhaowei Chen, 2020 42 41% 10,147 moderate low clinical improvementdetailed results ACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20]
ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
AVIFAVIR, 2020 0.53 [0.13; 2.19]
BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
Cadegiani, 2021 2.28 [1.95; 2.66]
CAN-COVID, 2020 1.39 [0.76; 2.54]
Cao, 2020 1.31 [0.94; 1.83]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
CAPSID, 2021 1.58 [0.71; 3.49]
Chachar, 2020 1.19 [0.38; 3.72]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
ConPlas-19, 2020 0.95 [0.60; 1.52]
COV-BARRIER, 2021 1.25 [1.04; 1.50]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
Dongsheng Wang, 2020 2.37 [0.40; 13.96]
Edalatifard, 2020 12.00 [2.39; 60.20]
EMPACTA, 2020 1.15 [0.90; 1.47]
Ghandehari, 2020 1.31 [1.00; 1.71]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
Gunst JD, 2021 1.14 [0.83; 1.57]
ITAC, 2022 1.06 [0.77; 1.45]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Li, 2020 1.40 [0.79; 2.49]
Lopardo, 2021 1.61 [0.75; 3.49]
Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
NCT04542694, 2020 2.10 [1.04; 4.24]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
Okumuş, 2020 1.51 [0.54; 4.24]
ORCHID, 2020 1.02 [0.73; 1.42]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
REMAP-CAP sarilumab, 2021 1.76 [1.12; 2.78]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 0.83 [0.67; 1.03]
REMAP-CAP, fixed 7-day course, 2020 1.43 [0.91; 2.26]
REMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95]
Rocco, 2020 0.81 [0.52; 1.27]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36]
sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
Tang, 2020 1.01 [0.59; 1.74]
Tang X, 2020 1.04 [0.67; 1.62]
Udwadia, 2020 1.75 [1.10; 2.79]
1.22 [1.12 ; 1.33 ] ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, AVIFAVIR, 2020, BACC Bay Tocilizumab Trial, 2020, Bennett-Guerrero, 2021, Cadegiani, 2021, CAN-COVID, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, CAPSID, 2021, Chachar, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, ConPlas-19, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Davoudi-Monfared, 2020, Dongsheng Wang, 2020, Edalatifard, 2020, EMPACTA, 2020, Ghandehari, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, ITAC, 2022, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Li, 2020, Lopardo, 2021, Lou (FAVIPIRAVIR), 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, NIH NIAID ACTT-1, 2020, Okumuş, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rocco, 2020, Ruzhentsova T, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Tang, 2020, Tang X, 2020, Udwadia, 2020 61 67% 19,091 moderate low clinical improvement (14-day)detailed results ACTT-2 (Kalil), 2020 1.30 [1.03; 1.64]
AVIFAVIR, 2020 0.53 [0.13; 2.19]
Cadegiani, 2021 2.28 [1.95; 2.66]
Cao, 2020 1.94 [1.09; 3.48]
CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
Chen, 2020 0.56 [0.13; 2.48]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
COV-BARRIER, 2021 1.28 [1.05; 1.56]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Li, 2020 2.27 [0.90; 5.72]
Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
Lou Y, 2020 1.50 [0.26; 8.82]
ORCHID, 2020 1.02 [0.73; 1.42]
Pandit, 2021 8.77 [0.94; 81.67]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
REMAP-CAP sarilumab, 2021 1.86 [1.20; 2.87]
REMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03]
REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64]
Ruzhentsova T, 2020 1.28 [1.05; 1.56]
Sadeghi , 2020 3.63 [1.02; 12.93]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Tang X, 2020 1.33 [0.57; 3.11]
1.24 [1.05 ; 1.46 ] ACTT-2 (Kalil), 2020, AVIFAVIR, 2020, Cadegiani, 2021, Cao, 2020, CAP-China (Wang et al.), 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Kalil (ACTT-3), 2021, Li, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, ORCHID, 2020, Pandit, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP sarilumab, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Ruzhentsova T, 2020, Sadeghi , 2020, Shashi Bhushan, 2021, Shu, 2020, Tang X, 2020 30 74% 10,467 moderate low clinical improvement (21-day)detailed results Li T, 2020 2.09 [0.04; 119.96]
2.09 [0.04 ; 119.96 ] Li T, 2020 1 0% 18 NA not evaluable clinical improvement (28-day)detailed results Abuhasira, 2021 1.70 [0.52; 5.49]
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.27 [1.03; 1.57]
Bennett-Guerrero, 2021 1.02 [0.25; 4.20]
Cadegiani, 2021 1.81 [1.60; 2.05]
Cao, 2020 1.59 [0.84; 3.03]
CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04]
COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
Li, 2020 1.42 [0.65; 3.10]
NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76]
ORCHID, 2020 0.97 [0.69; 1.37]
O’Donnell, 2021 1.38 [0.73; 2.61]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Ruzhentsova T, 2020 1.11 [0.96; 1.29]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 3.15 [1.39; 7.14]
Udwadia, 2020 1.75 [1.10; 2.79]
1.36 [1.16 ; 1.59 ] Abuhasira, 2021, ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, Bennett-Guerrero, 2021, Cadegiani, 2021, Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Ruzhentsova T, 2020, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Udwadia, 2020 23 67% 7,729 moderate low clinical improvement (7-day)detailed results ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
Cao, 2020 3.16 [0.62; 16.06]
CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
Chachar, 2020 1.19 [0.38; 3.72]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35]
COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09]
ITAC, 2022 1.06 [0.77; 1.45]
Kirti, 2021 0.90 [0.77; 1.06]
Li, 2020 0.98 [0.27; 3.58]
Lou Y, 2020 1.00 [0.05; 18.57]
NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
NCT04542694, 2020 2.10 [1.04; 4.24]
ORCHID, 2020 1.16 [0.84; 1.61]
Rocco, 2020 0.81 [0.52; 1.27]
Ruzhentsova T, 2020 1.50 [1.02; 2.21]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
Shu, 2020 6.72 [1.50; 30.07]
1.17 [1.00 ; 1.37 ] ACTIV-3/TICO LY-CoV555 , 2020, Cao, 2020, CAP-China (Wang et al.), 2020, Chachar, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, ITAC, 2022, Kirti, 2021, Li, 2020, Lou Y, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, ORCHID, 2020, Rocco, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Shu, 2020 19 49% 4,996 moderate critical clinical improvement (time to event analysis only)detailed results Abuhasira, 2021 1.22 [0.70; 2.14]
ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
Cao, 2020 1.31 [0.94; 1.83]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
EMPACTA, 2020 1.15 [0.90; 1.47]
FACCT Trial, 2021 0.85 [0.62; 1.16]
GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44]
GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42]
Gunst JD, 2021 1.14 [0.83; 1.57]
HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
Li, 2020 1.40 [0.79; 2.49]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
ORCHID, 2020 0.97 [0.69; 1.36]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
Rahmani, 2020 3.41 [1.33; 8.73]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
sarimulab phase 2 low dose, 0 0.96 [0.53; 1.73]
Shenoy S, 2021 0.99 [0.77; 1.28]
Shinkai, 2021 1.40 [0.91; 2.15]
SPRINTER, 2022 1.02 [0.81; 1.28]
Tang, 2020 1.01 [0.59; 1.74]
Tang X, 2020 1.04 [0.67; 1.62]
Udwadia, 2020 1.75 [1.10; 2.79]
Wu X, 2020 2.00 [0.71; 5.66]
1.14 [1.08 ; 1.21 ] Abuhasira, 2021, ACTT-2 (Kalil), 2020, Bennett-Guerrero, 2021, Cao, 2020, CAP-China (Wang et al.), 2020, ConPlas-19, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, EMPACTA, 2020, FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, NCT04523831 (Mahmud), 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, Ruzhentsova T, 2020, sarimulab phase 2 low dose, 0, Shenoy S, 2021, Shinkai, 2021, SPRINTER, 2022, Tang, 2020, Tang X, 2020, Udwadia, 2020, Wu X, 2020 34 16% 9,645 moderate critical death or ventilationdetailed results ACTT-2 (Kalil), 2020 0.69 [0.50; 0.95]
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.82 [0.63; 1.07]
BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
CAPE-COVID, 2020 0.71 [0.37; 1.35]
COLCOVID, 2021 0.83 [0.67; 1.02]
CONCOR-1, 2021 1.16 [0.94; 1.43]
ConPlas-19, 2020 0.94 [0.86; 1.02]
CORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52]
CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
DAWN-Plasma, 2021 1.01 [0.64; 1.59]
EMPACTA, 2020 0.56 [0.32; 0.97]
Fragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96]
Gonzalez (HCQ), 2020 0.69 [0.22; 2.21]
Gonzalez (IVER), 2020 0.89 [0.30; 2.64]
HYCOVID, 2020 1.12 [0.45; 2.79]
LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
Menichetti, 2021 0.88 [0.59; 1.32]
ORCHID, 2020 1.13 [0.60; 2.13]
RAPID (Sholzberg), 2021 0.59 [0.34; 1.02]
RECOVERY, 2020 1.14 [1.03; 1.27]
RECOVERY, 2021 0.85 [0.78; 0.93]
RECOVERY, 2022 0.90 [0.81; 0.99]
RECOVERY (AZI, Horby), 2020 0.95 [0.87; 1.03]
RECOVERY (colchicine), 2021 1.02 [0.96; 1.09]
RECOVERY (plasma), 2021 0.99 [0.93; 1.05]
RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92]
RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01]
REMAP-CAP, fixed 7-day course, 2020 2.74 [1.16; 6.46]
REMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Rutgers, 2021 0.65 [0.43; 0.99]
sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82]
sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44]
SOLIDARITY (interferon), 2020 1.05 [0.90; 1.23]
SOLIDARITY (remdesivir), 2020 0.97 [0.85; 1.10]
SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
SPRINTER, 2022 0.85 [0.45; 1.61]
STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
Veiga, 2021 1.54 [0.65; 3.63]
0.92 [0.87 ; 0.97 ] ACTT-2 (Kalil), 2020, ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, BACC Bay Tocilizumab Trial, 2020, CAPE-COVID, 2020, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, DAWN-Plasma, 2021, EMPACTA, 2020, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYCOVID, 2020, LIVE-AIR (Temesgen), 2021, Menichetti, 2021, ORCHID, 2020, RAPID (Sholzberg), 2021, RECOVERY, 2020, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SOLIDARITY (interferon), 2020, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, SPRINTER, 2022, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Veiga, 2021 42 54% 77,616 moderate critical hospital dischargedetailed results ACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20]
CAPE-COVID, 2020 1.67 [0.87; 3.19]
COLCHIVID, 2021 1.13 [0.76; 1.67]
ConPlas-19, 2020 1.02 [0.82; 1.28]
Davoudi-Monfared, 2020 1.96 [0.76; 5.03]
DAWN-Plasma, 2021 1.06 [0.87; 1.30]
Duarte, 2020 2.15 [1.18; 3.93]
EMPACTA, 2020 1.16 [0.90; 1.49]
FACCT Trial, 2021 0.88 [0.64; 1.21]
Fragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55]
Gonzalez (HCQ), 2020 1.38 [0.46; 4.16]
Gonzalez (IVER), 2020 0.71 [0.15; 3.40]
HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
Kirti, 2021 1.20 [0.73; 1.98]
Li T, 2020 10.00 [1.03; 97.50]
Mobarak (DISCOVER), 2021 1.01 [0.95; 1.08]
Murai, 2020 0.99 [0.71; 1.38]
Patel, 2021 0.57 [0.12; 2.68]
Rahmani, 2020 3.44 [0.64; 18.49]
RECOVERY, 2020 0.98 [0.91; 1.05]
RECOVERY (Aspirin), 2022 1.06 [1.02; 1.10]
RECOVERY (AZI, Horby), 2020 1.04 [0.98; 1.10]
RECOVERY (colchicine), 2021 0.98 [0.94; 1.03]
RECOVERY (plasma), 2021 0.99 [0.92; 1.07]
RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31]
RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92]
RIVET-COV (Mohan) (12mg and 24mg), 2021 2.31 [0.66; 8.04]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
Shenoy S, 2021 1.06 [0.85; 1.32]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
SPRINTER, 2022 1.06 [0.89; 1.27]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
Udwadia, 2020 1.41 [0.97; 2.03]
University of Minnesota, 2020 0.64 [0.37; 1.11]
1.04 [1.00 ; 1.08 ] ACTIV-3/TICO LY-CoV555 , 2020, CAPE-COVID, 2020, COLCHIVID, 2021, ConPlas-19, 2020, Davoudi-Monfared, 2020, DAWN-Plasma, 2021, Duarte, 2020, EMPACTA, 2020, FACCT Trial, 2021, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYDRA (Hernandez-Cardenas), 2021, Kirti, 2021, Li T, 2020, Mobarak (DISCOVER), 2021, Murai, 2020, Patel, 2021, Rahmani, 2020, RECOVERY, 2020, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rosas (REMDACTA), 2021, Shenoy S, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, SPRINTER, 2022, Synairgen SG016, 2020, Udwadia, 2020, University of Minnesota, 2020 36 48% 68,985 moderate critical hospitalizationdetailed results EPIC-SR, 0 0.29 [0.08; 1.07]
Holubar M, 2021 0.12 [0.01; 2.26]
Jagannathan, 2020 1.00 [0.14; 7.34]
University of Minnesota, 2020 1.63 [0.94; 2.85]
0.67 [0.20 ; 2.17 ] EPIC-SR, 0, Holubar M, 2021, Jagannathan, 2020, University of Minnesota, 2020 4 63% 1,328 low not evaluable mechanical ventilationdetailed results Abd-Elsalam, 2021 1.00 [0.20; 5.11]
Abuhasira, 2021 1.62 [0.41; 6.39]
ACTT-2 (Kalil), 2020 0.64 [0.44; 0.93]
AlQahtani, 2020 0.67 [0.22; 2.02]
Ansarin, 2020 0.09 [0.01; 0.73]
Cadegiani, 2021 0.10 [0.04; 0.29]
CAPE-COVID, 2020 0.95 [0.44; 2.04]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COPLA-II trial, 2020 0.58 [0.37; 0.92]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Davoudi-Monfared, 2020 0.72 [0.29; 1.76]
Duarte, 2020 0.30 [0.03; 3.01]
Fragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.70 [0.52; 0.95]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.85 [0.68; 1.06]
GRECCO-19, 2020 0.17 [0.02; 1.48]
GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30]
GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45]
Gunst JD, 2021 2.27 [0.62; 8.26]
Hamed, 2021 3.15 [0.57; 17.48]
Holm K, 2021 0.39 [0.01; 12.68]
I-TECH (Lim), 2022 0.41 [0.13; 1.30]
Jamaati, 2021 1.38 [0.45; 4.20]
Jamali Moghadam Siahkali, 2021 1.30 [0.31; 5.40]
Jun C, 2020 2.07 [0.06; 66.79]
Kirti, 2021 0.20 [0.00; 8.69]
Kumari, 2020 0.76 [0.33; 1.76]
Li T, 2020 0.40 [0.04; 3.90]
Lou Y, 2020 2.11 [0.06; 70.98]
Mahajan, 2021 2.27 [0.39; 13.27]
Metcovid, 2020 1.19 [0.56; 2.49]
Mobarak S (DISCOVER), 2021 1.52 [0.72; 3.19]
Murai, 2020 0.49 [0.21; 1.14]
NCT04397757, 2021 0.41 [0.13; 1.35]
O’Donnell, 2021 1.50 [0.47; 4.82]
PLACID, 2020 0.99 [0.54; 1.81]
PlasmAr, 2020 0.86 [0.39; 1.93]
Rahmani, 2020 0.29 [0.05; 1.56]
RAPID (Sholzberg), 2021 0.70 [0.32; 1.54]
RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69]
RECOVERY, 2022 0.87 [0.74; 1.02]
RECOVERY (AZI, Horby), 2020 0.92 [0.79; 1.07]
RECOVERY (colchicine), 2021 1.04 [0.93; 1.16]
RECOVERY (plasma), 2021 0.98 [0.88; 1.09]
RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
Rutgers, 2021 0.65 [0.35; 1.24]
Sadeghi , 2020 0.37 [0.09; 1.58]
Sakoulas, 2020 0.19 [0.03; 1.11]
sarilumab phase 2 high dose, 0 0.27 [0.10; 0.71]
sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
Sekhavati, 2020 0.16 [0.01; 3.19]
Shahbaznejad, 2020 2.24 [0.19; 25.88]
Shu, 2020 0.59 [0.02; 14.04]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38]
SOLIDARITY (remdesivir), 2020 1.04 [0.87; 1.23]
Tabarsi, 2020 1.49 [0.59; 3.78]
Udwadia, 2020 0.06 [0.01; 0.83]
University of Minnesota, 2020 1.34 [0.66; 2.73]
Yakoot, 2020 0.38 [0.07; 2.08]
0.83 [0.75 ; 0.92 ] Abd-Elsalam, 2021, Abuhasira, 2021, ACTT-2 (Kalil), 2020, AlQahtani, 2020, Ansarin, 2020, Cadegiani, 2021, CAPE-COVID, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, COPLA-II trial, 2020, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Duarte, 2020, Fragoso-Saavedra (PISCO), 2020, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Hamed, 2021, Holm K, 2021, I-TECH (Lim), 2022, Jamaati, 2021, Jamali Moghadam Siahkali, 2021, Jun C, 2020, Kirti, 2021, Kumari, 2020, Li T, 2020, Lou Y, 2020, Mahajan, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, Murai, 2020, NCT04397757, 2021, O’Donnell, 2021, PLACID, 2020, PlasmAr, 2020, Rahmani, 2020, RAPID (Sholzberg), 2021, RCT-TCZ-COVID-19, 2021, RECOVERY, 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY dexamethasone, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rutgers, 2021, Sadeghi , 2020, Sakoulas, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, SAVE-MORE, 2021, Sekhavati, 2020, Shahbaznejad, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, SOLIDARITY (remdesivir), 2020, Tabarsi, 2020, Udwadia, 2020, University of Minnesota, 2020, Yakoot, 2020 67 39% 60,126 moderate critical mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
DAWN-Plasma, 2021 1.08 [0.65; 1.80]
Fragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42]
Guardado-Mendoza, 2022 0.26 [0.09; 0.72]
Gunst JD, 2021 0.69 [0.14; 3.42]
Udwadia, 2020 0.06 [0.01; 0.83]
0.60 [0.32 ; 1.10 ] CP-COVID-19, 2021, DAWN-Plasma, 2021, Fragoso-Saavedra (PISCO), 2020, Guardado-Mendoza, 2022, Gunst JD, 2021, Udwadia, 2020 6 49% 1,066 moderate serious radiologic improvement (14-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28]
ELACOI (Standard of care), 2020 0.18 [0.01; 3.99]
Jamaati, 2021 4.89 [1.15; 20.79]
Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28]
Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88]
Tabarsi, 2020 2.33 [0.45; 12.00]
2.13 [1.30 ; 3.50 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Jamaati, 2021, Rashad (CLARI vs SoC), 2021, Rashad A (AZI vs SoC), 2021, Tabarsi, 2020 6 21% 584 moderate not evaluable radiologic improvement (7-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09]
ELACOI (Standard of care), 2020 0.08 [0.00; 1.71]
Zhaowei Chen, 2020 3.43 [1.10; 10.70]
0.40 [0.02 ; 6.97 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Zhaowei Chen, 2020 3 77% 108 moderate not evaluable Recovery (time to event analysis only)detailed results SPRINTER, 2022 1.02 [0.81; 1.28]
1.02 [0.81 ; 1.28 ] SPRINTER, 2022 1 0% 623 NA not evaluable viral clearance detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Chaccour, 2020 0.92 [0.77; 1.09]
CP-COVID-19, 2021 1.12 [0.16; 7.84]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Esquivel-Moynelo, 2020 3.26 [1.53; 6.95]
HC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75]
Holubar M, 2021 0.76 [0.48; 1.20]
Jagannathan, 2020 0.81 [0.56; 1.18]
Jun C, 2020 0.82 [0.36; 1.87]
Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
NCT04542694, 2020 13.03 [2.96; 57.24]
Pandit, 2021 2.33 [0.55; 9.83]
Raman, 2021 36.42 [10.85; 122.18]
Rastogi, 2020 6.33 [1.54; 26.00]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
Tang, 2020 0.85 [0.58; 1.23]
Tang X, 2020 1.78 [1.06; 3.00]
Udwadia, 2020 1.37 [0.94; 1.98]
1.60 [1.20 ; 2.13 ] AVIFAVIR, 2020, Chaccour, 2020, CP-COVID-19, 2021, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Esquivel-Moynelo, 2020, HC-nCoV (Shanghai), 2020, Holubar M, 2021, Jagannathan, 2020, Jun C, 2020, Lou (FAVIPIRAVIR), 2020, NCT04542694, 2020, Pandit, 2021, Raman, 2021, Rastogi, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020, Salman, 2020, Shashi Bhushan, 2021, Tang, 2020, Tang X, 2020, Udwadia, 2020 23 75% 2,064 moderate critical viral clearance (time to event analysis only)detailed results Ahmed, 2020 4.10 [1.12; 14.99]
Esquivel-Moynelo, 2020 3.26 [1.53; 6.95]
Holubar M, 2021 0.76 [0.48; 1.20]
Jagannathan, 2020 0.81 [0.56; 1.18]
Jun C, 2020 0.82 [0.36; 1.87]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Tang, 2020 0.85 [0.58; 1.23]
Tang X, 2020 1.78 [1.06; 3.00]
Udwadia, 2020 1.37 [0.94; 1.98]
1.22 [0.91 ; 1.62 ] Ahmed, 2020, Esquivel-Moynelo, 2020, Holubar M, 2021, Jagannathan, 2020, Jun C, 2020, Ruzhentsova T, 2020, Tang, 2020, Tang X, 2020, Udwadia, 2020 9 67% 988 moderate not evaluable viral clearance by day 14detailed results Ahmed, 2020 4.10 [1.12; 14.99]
AVIFAVIR, 2020 3.08 [0.62; 15.39]
Bukhari, 2021 0.91 [0.02; 46.94]
Chen, 2020 1.42 [0.26; 7.76]
CP-COVID-19, 2021 1.51 [0.33; 6.94]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Esquivel-Moynelo, 2020 5.90 [0.28; 122.94]
Kirenga, 2021 0.95 [0.76; 1.19]
Li T, 2020 1.00 [0.03; 34.67]
Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
Lou Y, 2020 0.12 [0.01; 2.86]
Pandit, 2021 10.23 [1.12; 93.35]
Raman, 2021 36.42 [10.85; 122.18]
Ruzhentsova T, 2020 0.99 [0.93; 1.06]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
1.15 [0.61 ; 2.18 ] Ahmed, 2020, AVIFAVIR, 2020, Bukhari, 2021, Chen, 2020, CP-COVID-19, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Esquivel-Moynelo, 2020, Kirenga, 2021, Li T, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Pandit, 2021, Raman, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021 16 91% 2,274 moderate low viral clearance by day 7detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Bukhari, 2021 11.56 [3.53; 37.91]
Chaccour, 2020 0.92 [0.77; 1.09]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91]
ELACOI (Standard of care), 2020 0.67 [0.10; 4.58]
Esquivel-Moynelo, 2020 3.09 [1.04; 9.17]
Jun C, 2020 0.58 [0.14; 2.48]
Kirenga, 2021 0.87 [0.65; 1.16]
Kirti, 2021 0.80 [0.43; 1.50]
Lou Y, 2020 1.50 [0.26; 8.82]
Pandit, 2021 2.33 [0.55; 9.83]
PLACID, 2020 1.20 [1.00; 1.44]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
Ruzhentsova T, 2020 1.05 [0.92; 1.20]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.23 [1.00 ; 1.52 ] AVIFAVIR, 2020, Bukhari, 2021, Chaccour, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Esquivel-Moynelo, 2020, Jun C, 2020, Kirenga, 2021, Kirti, 2021, Lou Y, 2020, Pandit, 2021, PLACID, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020, Salman, 2020, Shashi Bhushan, 2021 17 63% 1,608 moderate low ICU admissiondetailed results Abd-Elsalam, 2020 0.83 [0.35; 1.95]
Abuhasira, 2021 1.96 [0.51; 7.52]
Ansarin, 2020 0.14 [0.03; 0.67]
COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69]
COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Duarte, 2020 0.73 [0.18; 2.97]
Entrenas (Pilot Calcifediol), 2020 0.03 [0.00; 0.27]
FACCT Trial, 2021 1.42 [0.79; 2.55]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.87 [0.69; 1.10]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.99 [0.56; 1.75]
GLUCOCOVID, 2020 0.85 [0.27; 2.67]
Gunst JD, 2021 0.80 [0.34; 1.90]
Hamed, 2021 3.15 [0.57; 17.48]
I-TECH (Lim), 2022 0.78 [0.27; 2.23]
Khamis, 2020 1.03 [0.35; 3.03]
Kirti, 2021 0.90 [0.30; 2.70]
Libster, 2020 0.33 [0.07; 1.58]
Lopardo, 2021 0.67 [0.35; 1.28]
Lopes MIF, 2020 1.06 [0.06; 18.45]
Lou (FAVIPIRAVIR), 2020 5.43 [0.21; 139.89]
Lou Y, 2020 2.11 [0.06; 70.98]
Murai, 2020 0.71 [0.37; 1.37]
ProPAC-COVID, 2021 1.24 [0.26; 5.80]
Rahmani, 2020 0.37 [0.14; 1.00]
RAPID (Sholzberg), 2021 0.79 [0.48; 1.30]
Rocco, 2020 4.11 [0.18; 91.83]
Rutgers, 2021 0.96 [0.55; 1.68]
Sekhavati, 2020 0.25 [0.05; 1.28]
Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64]
Tabarsi, 2020 0.56 [0.18; 1.74]
Tang X, 2020 1.00 [0.13; 7.45]
Yakoot, 2020 0.38 [0.07; 2.08]
0.81 [0.69 ; 0.95 ] Abd-Elsalam, 2020, Abuhasira, 2021, Ansarin, 2020, COL-COVID (Pascual-Figal), 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Duarte, 2020, Entrenas (Pilot Calcifediol), 2020, FACCT Trial, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GLUCOCOVID, 2020, Gunst JD, 2021, Hamed, 2021, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Libster, 2020, Lopardo, 2021, Lopes MIF, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Murai, 2020, ProPAC-COVID, 2021, Rahmani, 2020, RAPID (Sholzberg), 2021, Rocco, 2020, Rutgers, 2021, Sekhavati, 2020, Soin AS (COVINTOC), 2021, Tabarsi, 2020, Tang X, 2020, Yakoot, 2020 35 11% 5,335 moderate low Major thrombotic events or deathdetailed results REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.04 [0.80; 1.36]
1.04 [0.80 ; 1.36 ] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1 0% 1,091 NA not evaluable off oxygenationdetailed results Davoudi-Monfared, 2020 8.57 [1.43; 51.36]
HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
ILBS-COVID-02 (Bajpai M), 2020 0.26 [0.02; 2.88]
sarilumab phase 2 high dose, 0 1.99 [0.95; 4.15]
sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21]
1.35 [0.75 ; 2.46 ] Davoudi-Monfared, 2020, HYDRA (Hernandez-Cardenas), 2021, ILBS-COVID-02 (Bajpai M), 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0 5 55% 545 serious not evaluable recoverydetailed results Abdulamir, 2021 1.00 [0.20; 5.12]
ACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32]
ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37]
ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46]
COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Crippa (CANDIDATE), 2021 0.54 [0.15; 1.94]
GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37]
GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45]
Gunst JD, 2021 1.18 [0.87; 1.61]
Lanzoni, 2021 3.46 [1.05; 11.35]
Mobarak S (DISCOVER), 2021 0.97 [0.89; 1.05]
Synairgen SG016, 2020 2.19 [1.03; 4.67]
Talaschian, 2021 0.64 [0.14; 2.92]
Yakoot, 2020 1.60 [1.00; 2.55]
1.12 [1.01 ; 1.23 ] Abdulamir, 2021, ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, COV-BARRIER (critically ill), 2022, Crippa (CANDIDATE), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Lanzoni, 2021, Mobarak S (DISCOVER), 2021, Synairgen SG016, 2020, Talaschian, 2021, Yakoot, 2020 14 33% 3,707 moderate critical AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable cardiac arrestdetailed results SOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49]
1.92 [0.35 ; 10.49 ] SOLIDARITY (WHO study) HCQ, 2020 1 0% 1,853 NA not evaluable composite safety outcome detailed results ACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11]
1.56 [0.78 ; 3.11 ] ACTIV-3/TICO LY-CoV555 , 2020 1 0% 314 NA not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable related SAE (TRSAE)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11]
1.24 [0.50 ; 3.11 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
CAN-COVID, 2020 0.73 [0.45; 1.19]
Cao, 2020 0.52 [0.27; 1.01]
CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10]
COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77]
CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
CONCOR-1, 2021 1.27 [1.02; 1.58]
ConPlas-19, 2020 0.89 [0.43; 1.86]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Dongsheng Wang, 2020 0.91 [0.02; 47.31]
Edalatifard, 2020 0.81 [0.11; 6.17]
GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23]
GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14]
Gunst JD, 2021 1.84 [0.79; 4.30]
ITAC, 2022 0.98 [0.66; 1.46]
Jagannathan, 2020 1.00 [0.14; 7.34]
Krolewiecki, 2020 1.00 [0.03; 31.59]
Lanzoni, 2021 0.10 [0.01; 0.69]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
Lou Y, 2020 2.25 [0.38; 13.47]
Murai, 2020 0.99 [0.02; 50.39]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
NCT04542694, 2020 6.15 [0.30; 124.49]
NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96]
ORCHID, 2020 1.26 [0.56; 2.84]
O’Donnell, 2021 0.64 [0.35; 1.17]
Pandit, 2021 0.95 [0.02; 50.33]
PlasmAr, 2020 1.40 [0.78; 2.51]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32]
REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Ruzhentsova T, 2020 2.06 [0.09; 46.40]
Sadeghi , 2020 1.00 [0.02; 51.94]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Shi, 2020 1.08 [0.04; 32.96]
Shinkai, 2021 2.80 [0.14; 56.95]
Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13]
Talaschian, 2021 7.93 [0.37; 171.38]
Udwadia, 2020 1.03 [0.02; 52.48]
Veiga, 2021 1.66 [0.60; 4.59]
Yakoot, 2020 1.02 [0.02; 52.72]
1.00 [0.89 ; 1.12 ] BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, CONCOR-1, 2021, ConPlas-19, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Edalatifard, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, ITAC, 2022, Jagannathan, 2020, Krolewiecki, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Lou Y, 2020, Murai, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, Pandit, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rosas (REMDACTA), 2021, Ruzhentsova T, 2020, Sadeghi , 2020, Sekine (PLACOVID), 2021, Shi, 2020, Shinkai, 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Udwadia, 2020, Veiga, 2021, Yakoot, 2020 50 14% 15,448 moderate low superinfectiondetailed results ACTT-2 (Kalil), 2020 0.50 [0.32; 0.79]
CAPE-COVID, 2020 0.81 [0.49; 1.34]
Davoudi-Monfared, 2020 2.41 [0.75; 7.73]
Metcovid, 2020 0.98 [0.65; 1.47]
Rahmani, 2020 0.18 [0.02; 1.59]
0.80 [0.50 ; 1.27 ] ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, Davoudi-Monfared, 2020, Metcovid, 2020, Rahmani, 2020 5 61% 1,722 moderate not evaluable acute kidney injury detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18]
1.18 [0.44 ; 3.18 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable adverse eventsdetailed results Chaccour, 2020 1.00 [0.20; 5.07]
Chen, ChiCTR2000030054 - Chloroquine, 2020 4.00 [0.67; 23.73]
ChiCTR2000030054-HCQ (Chen), 2020 5.00 [0.85; 29.57]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78]
COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08]
COLCHIVID, 2021 1.63 [0.67; 3.95]
COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Dongsheng Wang, 2020 9.64 [2.76; 33.75]
Esquivel-Moynelo, 2020 1.33 [0.45; 3.92]
GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42]
GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80]
Gunst JD, 2021 0.80 [0.43; 1.51]
HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01]
Holubar M, 2021 2.07 [0.89; 4.83]
Jagannathan, 2020 1.33 [0.63; 2.78]
Kirenga, 2021 1.13 [0.50; 2.58]
Krolewiecki, 2020 1.53 [0.42; 5.58]
Lanzoni, 2021 0.18 [0.02; 1.95]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Murai, 2020 1.99 [0.07; 59.94]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
NCT04542694, 2020 1.00 [0.54; 1.85]
ORCHID, 2020 1.42 [0.87; 2.34]
Pandit, 2021 1.68 [0.47; 5.97]
Raman, 2021 1.36 [0.56; 3.30]
RECOVERY, 2020 1.36 [0.98; 1.90]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.25 [0.45; 3.47]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Ruzhentsova T, 2020 1.90 [0.96; 3.80]
Sakoulas, 2020 1.00 [0.02; 53.46]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shi, 2020 0.88 [0.38; 2.03]
Shinkai, 2021 19.54 [7.77; 49.11]
Shu, 2020 2.48 [0.05; 132.54]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87]
Tang, 2020 9.64 [0.50; 185.60]
TEACH, 2020 1.16 [0.55; 2.42]
Udwadia, 2020 6.36 [2.43; 16.65]
Veiga, 2021 1.65 [0.81; 3.37]
1.48 [1.26 ; 1.76 ] Chaccour, 2020, Chen, ChiCTR2000030054 - Chloroquine, 2020, ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, COLCHIVID, 2021, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Esquivel-Moynelo, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, HC-nCoV (Shanghai), 2020, Holubar M, 2021, Jagannathan, 2020, Kirenga, 2021, Krolewiecki, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Murai, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, ORCHID, 2020, Pandit, 2021, Raman, 2021, RECOVERY, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rosas (REMDACTA), 2021, Ruzhentsova T, 2020, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shi, 2020, Shinkai, 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, Tang, 2020, TEACH, 2020, Udwadia, 2020, Veiga, 2021 44 52% 12,273 moderate critical arrhythmiadetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69]
RECOVERY (AZI, Horby), 2020 0.90 [0.71; 1.15]
Sekhavati, 2020 0.98 [0.02; 50.38]
0.91 [0.72 ; 1.15 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, RECOVERY (AZI, Horby), 2020, Sekhavati, 2020 3 0% 8,290 moderate not evaluable deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81]
0.62 [0.23 ; 1.64 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64]
NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18]
0.95 [0.29 ; 3.10 ] CAP-China (Wang et al.), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, NIH NIAID ACTT-1, 2020 3 84% 1,712 moderate not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34]
0.97 [0.48 ; 1.93 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 low not evaluable long QTdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50]
COALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43]
2.39 [0.24 ; 23.87 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 80% 613 moderate not evaluable Major bleedingdetailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.80 [0.88; 3.67]
COALIZAO ACTION, 2021 2.50 [0.78; 8.06]
INSPIRATION, 2021 1.83 [0.53; 6.34]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.48 [0.74; 2.98]
1.75 [1.14 ; 2.69 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, COALIZAO ACTION, 2021, INSPIRATION, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 4 0% 4,494 moderate not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80]
0.82 [0.20 ; 3.29 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86]
COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11]
NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61]
1.26 [0.95 ; 1.67 ] CAP-China (Wang et al.), 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, NIH NIAID ACTT-1, 2020 4 0% 2,066 moderate not evaluable severe adverse eventsdetailed results Ansarin, 2020 1.00 [0.02; 51.70]
Patel, 2021 1.21 [0.02; 64.67]
1.10 [0.07 ; 18.09 ] Ansarin, 2020, Patel, 2021 2 0% 111 serious not evaluable Thromboembolic eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55]
COALIZAO ACTION, 2021 0.73 [0.41; 1.29]
INSPIRATION, 2021 1.07 [0.76; 1.49]
0.96 [0.73 ; 1.27 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALIZAO ACTION, 2021, INSPIRATION, 2021 3 0% 1,521 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-06 05:10 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290